Methotrexate Modulates the Kinetics of Adenosine in Humans in Vivo

Overview

Journal Ann Rheum Dis

Specialty Rheumatology

Date 2005 Nov 26

PMID 16308339

Citations 31

Authors

N P Riksen

P Barrera

P H H van den Broek

P L C M Van Riel

P Smits

G A Rongen

Affiliations

Soon will be listed here.

Abstract

Background: Animal studies suggest that the anti-inflammatory effect of methotrexate (MTX) is mediated by increased adenosine concentrations.

Objective: To assess the effect of MTX on the vasodilator effects of adenosine and the nucleoside uptake inhibitor, dipyridamole, in humans in vivo as a marker for changes in adenosine kinetics.

Methods: Ten patients with active arthritis were treated with MTX (15 mg/week). Measurements were performed before and after 12 weeks of treatment. At these time points, the activity of adenosine deaminase was measured in isolated lymphocytes, and forearm blood flow (FBF) was determined by venous occlusion plethysmography during administration of adenosine and dipyridamole into the brachial artery.

Results: The Vmax of adenosine deaminase in lymphocytes was reduced by MTX treatment (p<0.05). MTX significantly enhanced vasodilator response to adenosine (0.5 and 1.5 microg/min/dl of forearm tissue; mean (SE) FBF ratio increased from 1.2 (0.2) to 1.4 (0.2) and 2.2 (0.2) ml/dl/min, respectively, before and from 1.3 (0.1) to 1.8 (0.2) and 3.2 (0.5) ml/dl/min during MTX treatment; p<0.05). Also, dipyridamole-induced vasodilatation (30 and 100 microg/min/dl) was enhanced by MTX (FBF ratio increased from 1.2 (0.2) to 1.5 (0.3) and 1.8 (0.2), respectively, before and from 1.3 (0.1) to 1.8 (0.2) and 2.4 (0.4) during MTX treatment; p<0.05).

Conclusions: MTX treatment inhibits deamination of adenosine and potentiates adenosine-induced vasodilatation. Also dipyridamole-induced vasodilatation is enhanced by MTX treatment, suggesting an increased extracellular formation of adenosine. These effects on the adenosine kinetics in humans may contribute to the therapeutic efficacy of MTX.

Citing Articles

Impact of Disease-Modifying Antirheumatic Drugs on Cognitive Function in Older Adults with Rheumatoid Arthritis.

Fazel S, Carollo M, Tap L, Spini A, Trifiro G, Mattace-Raso F Drugs Aging. 2025; .

PMID: 40088377 DOI: 10.1007/s40266-025-01190-9.

Impact of Estrogen on Purinergic Signaling in Microvascular Disease.

Cassavaugh J, Longhi M, Robson S Int J Mol Sci. 2025; 26(5).

PMID: 40076726 PMC: 11900469. DOI: 10.3390/ijms26052105.

The Role of Adenosine in Overcoming Resistance in Sarcomas.

Cruz-Ramos M, Cabrera-Nieto S, Murguia-Perez M, Fajardo-Espinoza F Int J Mol Sci. 2024; 25(22).

PMID: 39596278 PMC: 11594806. DOI: 10.3390/ijms252212209.

Combination of Methotrexate and Resveratrol Reduces Pro-Inflammatory Chemokines in Human THP-1 Cells.

Al-Nasser M, Al-Saeedi M, Alhowaiti S, Shinwari Z, Alhamlan F, Alothaid H J Inflamm Res. 2024; 17:8085-8098.

PMID: 39507267 PMC: 11539838. DOI: 10.2147/JIR.S482503.

Systematic review and network meta-analysis on the efficacy and safety of parmacotherapy for hand osteoarthritis.

Wu R, Peng Q, Wang W, Zheng J, Zhou Y, Yang Q PLoS One. 2024; 19(5):e0298774.

PMID: 38722915 PMC: 11081354. DOI: 10.1371/journal.pone.0298774.

References

Rongen G, Floras J, Lenders J, Thien T, Smits P . Cardiovascular pharmacology of purines. Clin Sci (Lond). 1997; 92(1):13-24. DOI: 10.1042/cs0920013. View

Rongen G, Ginneken E, Thien T, Lutterman J, Smits P . Preserved vasodilator response to adenosine in insulin-dependent diabetes mellitus. Eur J Clin Invest. 1996; 26(3):192-8. DOI: 10.1046/j.1365-2362.1996.110264.x. View

Morabito L, Montesinos M, Schreibman D, Balter L, Thompson L, Resta R . Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5'-nucleotidase-mediated conversion of adenine nucleotides. J Clin Invest. 1998; 101(2):295-300. PMC: 508567. DOI: 10.1172/JCI1554. View

Petrie J, Ueda S, Morris A, Murray L, Elliott H, Connell J . How reproducible is bilateral forearm plethysmography?. Br J Clin Pharmacol. 1998; 45(2):131-9. PMC: 1873348. DOI: 10.1046/j.1365-2125.1998.00656.x. View

Snoeck E, Ver Donck K, Jacqmin P, Van Belle H, Dupont A, Van Peer A . Physiological red blood cell kinetic model to explain the apparent discrepancy between adenosine breakdown inhibition and nucleoside transporter occupancy of draflazine. J Pharmacol Exp Ther. 1998; 286(1):142-9. View

Bellamy M, McDowell I, Ramsey M, Brownlee M, Bones C, Newcombe R . Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in healthy adults. Circulation. 1998; 98(18):1848-52. DOI: 10.1161/01.cir.98.18.1848. View

Fredholm B, BATTIG K, Holmen J, Nehlig A, Zvartau E . Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev. 1999; 51(1):83-133. View

Deussen A, Stappert M, Schafer S, Kelm M . Quantification of extracellular and intracellular adenosine production: understanding the transmembranous concentration gradient. Circulation. 1999; 99(15):2041-7. DOI: 10.1161/01.cir.99.15.2041. View

Baggott J, Morgan S, SAMS W, Linden J . Urinary adenosine and aminoimidazolecarboxamide excretion in methotrexate-treated patients with psoriasis. Arch Dermatol. 1999; 135(7):813-7. DOI: 10.1001/archderm.135.7.813. View

10.

Egan L, Sandborn W, Mays D, Tremaine W, Lipsky J . Plasma and rectal adenosine in inflammatory bowel disease: effect of methotrexate. Inflamm Bowel Dis. 1999; 5(3):167-73. DOI: 10.1097/00054725-199908000-00004. View

11.

Dolezalova P, Krijt J, Chladek J, Nemcova D, Hoza J . Adenosine and methotrexate polyglutamate concentrations in patients with juvenile arthritis. Rheumatology (Oxford). 2004; 44(1):74-9. DOI: 10.1093/rheumatology/keh401. View

12.

Riksen N, Rongen G, Boers G, Blom H, van den Broek P, Smits P . Enhanced cellular adenosine uptake limits adenosine receptor stimulation in patients with hyperhomocysteinemia. Arterioscler Thromb Vasc Biol. 2004; 25(1):109-14. DOI: 10.1161/01.ATV.0000150651.85907.69. View

13.

Cronstein B . Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev. 2005; 57(2):163-72. DOI: 10.1124/pr.57.2.3. View

14.

Riksen N, Oyen W, Ramakers B, van den Broek P, Engbersen R, Boerman O . Oral therapy with dipyridamole limits ischemia-reperfusion injury in humans. Clin Pharmacol Ther. 2005; 78(1):52-9. DOI: 10.1016/j.clpt.2005.03.003. View

15.

Laghi Pasini F, Capecchi P, Di Perri T . Adenosine plasma levels after low dose methotrexate administration. J Rheumatol. 1998; 24(12):2492-3. View

16.

Riksen N, van Ginneken E, van den Broek P, Smits P, Rongen G . In vivo evidence against a role for adenosine in the exercise pressor reflex in humans. J Appl Physiol (1985). 2005; 99(2):522-7. DOI: 10.1152/japplphysiol.00108.2005. View

17.

Smolenska Z, Kaznowska Z, Zarowny D, Simmonds H, Smolenski R . Effect of methotrexate on blood purine and pyrimidine levels in patients with rheumatoid arthritis. Rheumatology (Oxford). 1999; 38(10):997-1002. DOI: 10.1093/rheumatology/38.10.997. View

18.

Montesinos M, Yap J, Desai A, Posadas I, McCrary C, Cronstein B . Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine: evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat.... Arthritis Rheum. 2000; 43(3):656-63. DOI: 10.1002/1529-0131(200003)43:3<656::AID-ANR23>3.0.CO;2-H. View

19.

Landewe R, van den Borne B, Breedveld F, Dijkmans B . Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity. Lancet. 2000; 355(9215):1616-7. DOI: 10.1016/S0140-6736(00)02222-4. View

20.

Mattig S, Deussen A . Significance of adenosine metabolism of coronary smooth muscle cells. Am J Physiol Heart Circ Physiol. 2000; 280(1):H117-24. DOI: 10.1152/ajpheart.2001.280.1.H117. View